YIH
CCCC icon

Y-Intercept (HK)’s C4 Therapeutics CCCC Stock Holding History

Y-Intercept (HK)’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-52,521
Closed -$75.1K – 1600
2025
Q2 		$75.1K Buy
+52,521
New +$76.4K ﹤0.01% 1551
2025
Q1 		– Sell
-23,176
Closed -$83.4K – 1236
2024
Q4 		$83.4K Buy
+23,176
New +$115K 0.01% 1107
2024
Q1 		– Sell
-18,823
Closed -$106K – 1397
2023
Q4 		$106K Buy
+18,823
New +$42.9K 0.01% 1089
2023
Q3 		– Sell
-75,900
Closed -$209K – 1104
2023
Q2 		$209K Buy
75,900
+44,538
+142% +$143K 0.02% 926
2023
Q1 		$98.5K Buy
+31,362
New +$185K 0.01% 1057

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Y-Intercept (HK)'s CCCC Position: Q3 2025 in Review

Y-Intercept (HK) sold out of C4 Therapeutics (CCCC) in Q3 2025, closing a stake of 52,521 shares — an estimated $75.1K sold.

Y-Intercept (HK) first reported a position in CCCC in Q1 2023 and held it in 5 quarters. The position peaked at $209K in Q2 2023. 97 funds tracked by Wall St. Rank hold CCCC as of Q3 2025.

  • Y-Intercept (HK) reported no remaining C4 Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Y-Intercept (HK) sold 52,521 C4 Therapeutics shares in Q3 2025, an estimated $75.1K.
  • Y-Intercept (HK) first reported a position in C4 Therapeutics in Q1 2023 and held it in 5 quarters.
  • Y-Intercept (HK)'s C4 Therapeutics position peaked at $209K in Q2 2023.
  • 97 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.